Mr. Thomas Smeenk reports

HEMOSTEMIX ANNOUNCES AMENDMENT OF ITS $2.5 MILLION 5 YEAR CONVERTIBLE DEBENTURE ISSUED ON JUNE 11, 2021, RESULTING IN AN EXPECTED INTEREST SAVING OF APPROXIMATELY $570,000

Hemostemix Inc. has amended its $2.5-million five-year convertible debenture, which originally closed on June 11, 2021 (CD1), resulting in an expected interest saving of $569,868.

The four material amendments are summarized as follows:

1. Interest will be amended from 6 per cent per annum to nil from Jan. 1, 2023, to maturity (June 11, 2026), saving the company up to $569,868 of interest.
2. The company's conversion rights will be limited to allow conversion, at the originally stated conversion rate of 40 cents per common share, for any or all of the outstanding debentures at maturity, thus removing the company's ability to convert amounts prior to maturity that were generally limited to conversion amounts that would not increase the holder's share position to 10 per cent or more of the company's then outstanding shares.
3. The company will grant the holder the ability to convert at any time any or all of their debentures at the originally stated conversion rate of 40 cents per common share.
4. The security will be amended from unsecured to secured and will rank in a second secured position behind the already secured $2.75-million five-year secured debenture issued on April 25, 2022.

The amendments are subject to all necessary regulatory approvals, including acceptance from the TSX Venture Exchange.

About Hemostemix Inc.

Hemostemix is an autologous stem cell therapy company, founded in 2003. A winner of the World Economic Forum Technology Pioneer Award, the company has developed, has patented and is scaling a patient's blood-based stem cell therapeutics platform that includes angiogenic cell precursors, neuronal cell precursor and cardiomyocyte cell precursors.

We seek Safe Harbor.